Glioblastoma is a deadly type of brain cancer which progresses rapidly and kills victims within months. For nearly two decades, no significant progress has been made in developing an effective treatment against this malignancy. Now, a new preclinical study using animal models has unveiled a potential breakthrough that could eliminate these tumors.
The study, whose findings were published in the journal Nature, was conducted by scientists at the startup Trogenix. The team is made up of scientists at the Cancer Institute at University College London, the Royal Infirmary at Edinburgh, and the University of Edinburgh.
The team developed SSEs technology (Synthetic Super-Enhancers) that entails using a viral vector to carry genetic instructions into glioblastoma tumors. The genetic instructions tell the tumor cells to make a toxic substance within the cells themselves, and also cause the body’s immune system to target these cancer cells aggressively.
Using this technology, the team was able to cause the brain cancer tumors to shrink after administering one dose of the treatment. These results were observed in 1-2 weeks after treatment was administered, raising hope that the approach could deliver major results in a short time. Additionally, 83% of the treated animals eventually had their tumors disappear totally in an extra 2-3 weeks.
The researchers also documented the precise effects of this treatment in priming the immune system to go after the cancer cells only while leaving other cells untouched. For 11 months post-treatment, there was no tumor recurrence in the treated subjects.
This early study is also notable for not triggering any adverse events in the subjects. This is rare because existing cancer treatments often trigger different side effects that can be so severe that treatment has to be halted or the patients suffer serious impediments to their quality of life during and after treatment.
The team hopes to start trials involving human subjects this year in order to move the therapy quickly through the development process. Prof. Steve Pollard, Trogenix’s Chief Scientific Officer, said their study shows that what was previously taken to be impossible, that is, totally eliminating glioblastoma tumors while preventing recurrence for a long time, could now be achieved. This advanced “Trojan horse” method could mark a major shift in the way this deadly brain cancer is treated in the years to come.
As the team advances their approach through the next phases involving human participants, other companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also hitting their drug development milestones and the treatment options for people with a glioblastoma diagnosis could soon increase significantly.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.…
The immune system is capable of identifying and attacking cancer cells in the body. This process…
LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers…
LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness…
The shares of health insurers in the U.S. recorded gains after the Trump administration announced 2027 payment rate increases for Medicare…
Cancer research often relies on massive and complex datasets, which can take time and effort…